"Desvenlafaxine Succinate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.
| Descriptor ID |
D000069468
|
| MeSH Number(s) |
D02.033.415.510.500.303 D02.455.426.392.368.367.318.500 D02.455.426.559.389.657.265 D10.289.510.500.303
|
| Concept/Terms |
Desvenlafaxine Succinate- Desvenlafaxine Succinate
- Succinate, Desvenlafaxine
- O-desmethylvenlafaxine Succinate Monohydrate
- Monohydrate, O-desmethylvenlafaxine Succinate
- O desmethylvenlafaxine Succinate Monohydrate
- Succinate Monohydrate, O-desmethylvenlafaxine
- 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate
- O-desmethylvenlafaxine Succinate
- O desmethylvenlafaxine Succinate
- Succinate, O-desmethylvenlafaxine
WY 45,233- WY 45,233
- 45,233, WY
- WY-45,233
- WY45,233
- WY-45233
- WY45233
- WY 45233
- 45233, WY
Desvenlafaxine- Desvenlafaxine
- O-desmethylvenlafaxine
- O desmethylvenlafaxine
- 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
|
Below are MeSH descriptors whose meaning is more general than "Desvenlafaxine Succinate".
Below are MeSH descriptors whose meaning is more specific than "Desvenlafaxine Succinate".
This graph shows the total number of publications written about "Desvenlafaxine Succinate" by people in this website by year, and whether "Desvenlafaxine Succinate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 5 | 5 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Desvenlafaxine Succinate" by people in Profiles.
-
Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder. J Child Adolesc Psychopharmacol. 2016 12; 26(10):909-921.
-
Clayton AH, Hwang E, Kornstein SG, Tourian KA, Cheng RF, Abraham L, Mele L, Boucher M. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis. Int Clin Psychopharmacol. 2015 Nov; 30(6):307-15.
-
Clayton AH, Tourian KA, Focht K, Hwang E, Cheng RF, Thase ME. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry. 2015 May; 76(5):562-9.
-
Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr; 31(4):809-20.
-
Findling RL, Groark J, Chiles D, Ramaker S, Yang L, Tourian KA. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2014 May; 24(4):201-9.
-
Tourian K, Wang Y, Ii Y. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol. 2013 Jul; 28(4):206-13.
-
Liebowitz MR, Tourian KA, Hwang E, Mele L. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry. 2013 Mar 22; 13:94.
-
Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial. J Clin Psychiatry. 2013 Feb; 74(2):158-66.
-
Iwata N, Tourian KA, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 50?mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013 Jan; 19(1):5-14.
-
Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2012 Sep; 17(3):121-30.